Abstract Purpose of Review Osteonecrosis of the jaw (ONJ) is a rare and severe necrotic
bone disease reflecting a compromise in the body's osseous healing mechanisms and …

The present systematic review evaluates the safety of placing dental implants in patients
with a history of antiresorptive or antiangiogenic drug therapy. The Preferred Reporting …

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) has been associated with long-
term oral or intravenous administration of nitrogen-containing bisphosphonates (BPs) …

Hemoderivatives have utilized in an empirical manner, driven by clinical considerations,
leading to the development of a plethora of manufacturing protocols. The purpose of this …

Bisphosphonates-related osteonecrosis of the jaw (BRONJ) was firstly reported by Marx in
2003. Since 2014, the term medication-related osteonecrosis of the jaw (MRONJ) is …

The anti-angiogenic effects of bisphosphonates have been hypothesized as one of the
major etiologic factors in the development of medication-related osteonecrosis of the jaw …

Abstract Nitrogen-containing bisphosphonates (NBPs), compounds that are widely used in
the treatment of bone disorders, may cause side effects related to endothelial dysfunction …

Neridronate or ((6-amino-1-hydroxy-1-phosphonohexyl) phosphonic acid) is an amino-
bisphosphonate (BP) synthetized in Italy in 1986. Bisphosphonates are molecules with a …

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse effect of
antiresorptive and antiangiogenic therapies. MRONJ is identified by chronic wounds in the …

Medication-related osteonecrosis of the jaw (MRONJ) is a debilitating adverse effect of
bisphosphates, antiresorptive therapy or antiangiogenic agents that can potentially increase …